Killing kinetics of minocycline, doxycycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae

Miyuki Morozumi, Takafumi Okada, Takeshi Tajima, Kimiko Ubukata, Satoshi Iwata

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Macrolide-resistant Mycoplasma pneumoniae (MRMP) has emerged and is increasing worldwide. In a 2011 outbreak of MRMP infections in Japan, symptoms failed to improve in many patients who initially received macrolides; the therapeutic agent was then changed to minocycline (MIN), doxycycline (DOX) or tosufloxacin (TFX). In this study, the bactericidal effects of these three agents against MRMP were evaluated. Time-kill kinetics against MRMP and macrolide-susceptible M. pneumoniae (MSMP) were determined for 5 days at concentrations corresponding to the respective minimum inhibitory concentration (MIC) and 2 × MIC, i.e. 1 μg/mL and 2 μg/mL for MIN, 0.5 μg/mL and 1 μg/mL for DOX, and 0.5 μg/mL and 1 μg/mL for TFX. The post-antibiotic effects (PAE) of these agents in culture against MRMP were also examined based on their pharmacokinetic parameters in children. Following exposure of MRMP and MSMP to up to twice the respective MICs of MIN, DOX and TFX, viable cells initially numbering 106 CFU/mL had decreased similarly to 103 CFU/mL after 4 days. Clarithromycin and azithromycin showed good bactericidal action against MSMP but not against MRMP. PAEs against MRMP appeared superior with MIN and DOX compared with TFX. In infection with M. pneumoniae having a generation time exceeding 6 h, a therapeutic agent must be selected in consideration of pharmacokinetic parameters, not MICs alone.

Original languageEnglish
JournalInternational Journal of Antimicrobial Agents
DOIs
Publication statusAccepted/In press - 2016 Nov 4

Fingerprint

tosufloxacin
Mycoplasma pneumoniae
Minocycline
Doxycycline
Macrolides
Microbial Sensitivity Tests
Pharmacokinetics

Keywords

  • Doxycycline
  • Macrolide-resistant Mycoplasma pneumoniae
  • Minocycline
  • Paediatrics
  • Time-kill assay
  • Tosufloxacin

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Killing kinetics of minocycline, doxycycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae. / Morozumi, Miyuki; Okada, Takafumi; Tajima, Takeshi; Ubukata, Kimiko; Iwata, Satoshi.

In: International Journal of Antimicrobial Agents, 04.11.2016.

Research output: Contribution to journalArticle

Morozumi, Miyuki ; Okada, Takafumi ; Tajima, Takeshi ; Ubukata, Kimiko ; Iwata, Satoshi. / Killing kinetics of minocycline, doxycycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae. In: International Journal of Antimicrobial Agents. 2016.
@article{2868ef14ca744186949d8373f30da89f,
title = "Killing kinetics of minocycline, doxycycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae",
abstract = "Macrolide-resistant Mycoplasma pneumoniae (MRMP) has emerged and is increasing worldwide. In a 2011 outbreak of MRMP infections in Japan, symptoms failed to improve in many patients who initially received macrolides; the therapeutic agent was then changed to minocycline (MIN), doxycycline (DOX) or tosufloxacin (TFX). In this study, the bactericidal effects of these three agents against MRMP were evaluated. Time-kill kinetics against MRMP and macrolide-susceptible M. pneumoniae (MSMP) were determined for 5 days at concentrations corresponding to the respective minimum inhibitory concentration (MIC) and 2 × MIC, i.e. 1 μg/mL and 2 μg/mL for MIN, 0.5 μg/mL and 1 μg/mL for DOX, and 0.5 μg/mL and 1 μg/mL for TFX. The post-antibiotic effects (PAE) of these agents in culture against MRMP were also examined based on their pharmacokinetic parameters in children. Following exposure of MRMP and MSMP to up to twice the respective MICs of MIN, DOX and TFX, viable cells initially numbering 106 CFU/mL had decreased similarly to 103 CFU/mL after 4 days. Clarithromycin and azithromycin showed good bactericidal action against MSMP but not against MRMP. PAEs against MRMP appeared superior with MIN and DOX compared with TFX. In infection with M. pneumoniae having a generation time exceeding 6 h, a therapeutic agent must be selected in consideration of pharmacokinetic parameters, not MICs alone.",
keywords = "Doxycycline, Macrolide-resistant Mycoplasma pneumoniae, Minocycline, Paediatrics, Time-kill assay, Tosufloxacin",
author = "Miyuki Morozumi and Takafumi Okada and Takeshi Tajima and Kimiko Ubukata and Satoshi Iwata",
year = "2016",
month = "11",
day = "4",
doi = "10.1016/j.ijantimicag.2017.02.027",
language = "English",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",

}

TY - JOUR

T1 - Killing kinetics of minocycline, doxycycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae

AU - Morozumi, Miyuki

AU - Okada, Takafumi

AU - Tajima, Takeshi

AU - Ubukata, Kimiko

AU - Iwata, Satoshi

PY - 2016/11/4

Y1 - 2016/11/4

N2 - Macrolide-resistant Mycoplasma pneumoniae (MRMP) has emerged and is increasing worldwide. In a 2011 outbreak of MRMP infections in Japan, symptoms failed to improve in many patients who initially received macrolides; the therapeutic agent was then changed to minocycline (MIN), doxycycline (DOX) or tosufloxacin (TFX). In this study, the bactericidal effects of these three agents against MRMP were evaluated. Time-kill kinetics against MRMP and macrolide-susceptible M. pneumoniae (MSMP) were determined for 5 days at concentrations corresponding to the respective minimum inhibitory concentration (MIC) and 2 × MIC, i.e. 1 μg/mL and 2 μg/mL for MIN, 0.5 μg/mL and 1 μg/mL for DOX, and 0.5 μg/mL and 1 μg/mL for TFX. The post-antibiotic effects (PAE) of these agents in culture against MRMP were also examined based on their pharmacokinetic parameters in children. Following exposure of MRMP and MSMP to up to twice the respective MICs of MIN, DOX and TFX, viable cells initially numbering 106 CFU/mL had decreased similarly to 103 CFU/mL after 4 days. Clarithromycin and azithromycin showed good bactericidal action against MSMP but not against MRMP. PAEs against MRMP appeared superior with MIN and DOX compared with TFX. In infection with M. pneumoniae having a generation time exceeding 6 h, a therapeutic agent must be selected in consideration of pharmacokinetic parameters, not MICs alone.

AB - Macrolide-resistant Mycoplasma pneumoniae (MRMP) has emerged and is increasing worldwide. In a 2011 outbreak of MRMP infections in Japan, symptoms failed to improve in many patients who initially received macrolides; the therapeutic agent was then changed to minocycline (MIN), doxycycline (DOX) or tosufloxacin (TFX). In this study, the bactericidal effects of these three agents against MRMP were evaluated. Time-kill kinetics against MRMP and macrolide-susceptible M. pneumoniae (MSMP) were determined for 5 days at concentrations corresponding to the respective minimum inhibitory concentration (MIC) and 2 × MIC, i.e. 1 μg/mL and 2 μg/mL for MIN, 0.5 μg/mL and 1 μg/mL for DOX, and 0.5 μg/mL and 1 μg/mL for TFX. The post-antibiotic effects (PAE) of these agents in culture against MRMP were also examined based on their pharmacokinetic parameters in children. Following exposure of MRMP and MSMP to up to twice the respective MICs of MIN, DOX and TFX, viable cells initially numbering 106 CFU/mL had decreased similarly to 103 CFU/mL after 4 days. Clarithromycin and azithromycin showed good bactericidal action against MSMP but not against MRMP. PAEs against MRMP appeared superior with MIN and DOX compared with TFX. In infection with M. pneumoniae having a generation time exceeding 6 h, a therapeutic agent must be selected in consideration of pharmacokinetic parameters, not MICs alone.

KW - Doxycycline

KW - Macrolide-resistant Mycoplasma pneumoniae

KW - Minocycline

KW - Paediatrics

KW - Time-kill assay

KW - Tosufloxacin

UR - http://www.scopus.com/inward/record.url?scp=85020657107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020657107&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2017.02.027

DO - 10.1016/j.ijantimicag.2017.02.027

M3 - Article

C2 - 28579455

AN - SCOPUS:85020657107

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

ER -